These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25907701)

  • 1. Therapy: Facing up to biosimilar agents--the ACR position.
    Scheinberg M
    Nat Rev Rheumatol; 2015 Jun; 11(6):322-4. PubMed ID: 25907701
    [No Abstract]   [Full Text] [Related]  

  • 2. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
    Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
    Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
    Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
    Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Position paper of Italian rheumatologists on the use of biosimilar drugs.
    Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
    Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The advent of biosimilar therapies in rheumatology--"O brave new world".
    Scheinberg MA; Kay J
    Nat Rev Rheumatol; 2012 Jun; 8(7):430-6. PubMed ID: 22664834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
    Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
    [No Abstract]   [Full Text] [Related]  

  • 9. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
    Schulze-Koops H
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv1-iv3. PubMed ID: 28903541
    [No Abstract]   [Full Text] [Related]  

  • 11. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
    Kim SC; Sarpatwari A; Landon JE; Desai RJ
    Arthritis Rheumatol; 2020 Jun; 72(6):1036-1038. PubMed ID: 31943866
    [No Abstract]   [Full Text] [Related]  

  • 12. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
    Schaeverbeke T; Pham T; Richez C; Wendling D
    Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilars in rheumatology: perspective and concerns.
    Scheinberg MA; Azevedo VF
    Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
    [No Abstract]   [Full Text] [Related]  

  • 15. Biosimilars in rheumatology: understanding the rigor of their development.
    Goel N; Chance K
    Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patent watch: Have the biosimilar floodgates been opened in the United States?
    Brinckerhoff CC; Schorr K
    Nat Rev Drug Discov; 2015 May; 14(5):303-4. PubMed ID: 25924576
    [No Abstract]   [Full Text] [Related]  

  • 17. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
    Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
    Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves biosimilar version of infliximab.
    Traynor K
    Am J Health Syst Pharm; 2016 May; 73(10):604-6. PubMed ID: 27147206
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
    Scheinberg M; Castañeda-Hernández G
    Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in the Caribbean--key considerations.
    Cox SD
    West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.